
    
      A Phase 2, Open Label, Dose Escalation Study of Bermekimab (MABp1) in Patients with Moderate
      to Severe Atopic Dermatitis. The study is multi center and will consist of two dose levels:

      Group A (n=9): patients will receive a total of 4 x 200mg subcutaneous injections of
      bermekimab. Dosing will occur weekly from visit 1 to visit 4, inclusive.

      Group B (n=20): patients will receive a total of 8 x 400 mg subcutaneous injections of
      bermedimkb. Dosing will occur weekly from visit 1 to visit 8, inclusive.
    
  